Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW

Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...

Wilmington Healthcare

- PMLiVE

NHS awarded George Cross for efforts shown during the COVID-19 pandemic

The George Cross is the UK’s highest civilian gallantry award and has only been given to a collective group twice before

- PMLiVE

Expert review shows AstraZeneca’s COVID-19 vaccine is ‘equally effective’ as mRNA vaccines

The study informs policymakers about the optimal deployment of COVID-19 vaccines over the next 12 months

- PMLiVE

Hanover appoints Ian Dodge to its senior adviser panel

Dodge was the former national director of strategy, primary care and community services for NHS England

- PMLiVE

Accelerating patient recruitment post-COVID-19

COVID-19 has hugely affected clinical trials and patient recruitment, with the entire industry on hold for some time causing backlogs and delays most of the studies.

Innovative Trials

- PMLiVE

Genentech announces positive phase 3 trial results for haemophilia A

Results from the study showed that Hemlibra demonstrated ‘clinically meaningful’ bleed control in patients with moderate or mild haemophilia A, without factor VIII inhibitors

- PMLiVE

Boehringer Ingelheim and VisionHealth collaborate on distribution of digital Kata platform

The app provides therapy support to those with with asthma and chronic obstructive pulmonary disease

- PMLiVE

Evotech, Boehringer Ingelheim and bioMérieux launch joint venture to combat antimicrobial resistance

The joint company, Aurobac Therapeutics SAS, will create the next generation of antimicrobials along with actionable diagnostics to combat antimicrobial resistance

- PMLiVE

UK study reveals Omicron variant ‘substantially less likely’ to cause long Covid

The new study by King’s College London found that the odds of experiencing long COVID were between 20-50% less during the Omicron period versus the Delta period

Genesis Research & MAT logo

Genesis Research Acquires Market Access Transformation

Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services, has entered into a definitive agreement to acquire Market Access Transformation (“MAT”),...

Genesis Research Group

Communique Award Bedrock Healthcare Communications

Bedrock’s Accelerated Virtual Consensus Programme for Merck wins at Communiqué Awards

The award recognises outstanding achievement in flexing thinking and processes to ensure success.

Bedrock Healthcare Communications

ISPOR 2022: a retrospective

Genesis Research Group

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links